Regulatory Pfizer’s Hympavzi secures FDA expanded indications for haemophilia Pharmaceutical TechnologyPfizer has received approval from the FDA for an expanded indication of Hympavzi for the treatment of haemophilia A or B.HematologyRead full story pharminent June 9, 2026 (Last updated: June 9, 2026) Pharmaceutical Technology Pfizer has received approval from the FDA for an expanded indication of Hympavzi for the treatment of haemophilia A or B. Hematology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1BNext: ADA: AZ reveals oral GLP-1 data in obesity, diabetes Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
